BULL Pharmachem

Lenvatinib is a powerful multi-kinase inhibitor used to treat advanced cancers, including thyroid, liver, and kidney cancers. It works by blocking tumor angiogenesis and cell proliferation, effectively slowing disease progression and extending survival in patients with difficult-to-treat solid tumors.

Lenvatinib is a powerful multi-kinase inhibitor used to treat advanced cancers, including thyroid, liver, and kidney cancers. It works by blocking tumor angiogenesis and cell proliferation, effectively slowing disease progression and extending survival in patients with difficult-to-treat solid tumors.

Lenvatinib is a powerful multi-kinase inhibitor used to treat advanced cancers, including thyroid, liver, and kidney cancers. It works by blocking tumor angiogenesis and cell proliferation, effectively slowing disease progression and extending survival in patients with difficult-to-treat solid tumors.

Gefitinib tablets are used to treat non-small cell lung cancer (NSCLC) with EGFR mutations. By inhibiting the epidermal growth factor receptor (EGFR), it blocks cancer cell growth and spread, improving survival and quality of life in affected patients.

Pomalidomide is a potent immunomodulatory agent used primarily to treat multiple myeloma in patients unresponsive to prior therapies. It inhibits cancer cell growth, modulates the immune response, and reduces inflammation, often combined with dexamethasone for enhanced efficacy in relapsed or refractory cases.

Pomalidomide is a potent immunomodulatory agent used primarily to treat multiple myeloma in patients unresponsive to prior therapies. It inhibits cancer cell growth, modulates the immune response, and reduces inflammation, often combined with dexamethasone for enhanced efficacy in relapsed or refractory cases.

Pomalidomide is a potent immunomodulatory agent used primarily to treat multiple myeloma in patients unresponsive to prior therapies. It inhibits cancer cell growth, modulates the immune response, and reduces inflammation, often combined with dexamethasone for enhanced efficacy in relapsed or refractory cases.

Pomalidomide is a potent immunomodulatory agent used primarily to treat multiple myeloma in patients unresponsive to prior therapies. It inhibits cancer cell growth, modulates the immune response, and reduces inflammation, often combined with dexamethasone for enhanced efficacy in relapsed or refractory cases.

Pomalidomide is a potent immunomodulatory agent used primarily to treat multiple myeloma in patients unresponsive to prior therapies. It inhibits cancer cell growth, modulates the immune response, and reduces inflammation, often combined with dexamethasone for enhanced efficacy in relapsed or refractory cases.

Pomalidomide is a potent immunomodulatory agent used primarily to treat multiple myeloma in patients unresponsive to prior therapies. It inhibits cancer cell growth, modulates the immune response, and reduces inflammation, often combined with dexamethasone for enhanced efficacy in relapsed or refractory cases.

Pomalidomide is a potent immunomodulatory agent used primarily to treat multiple myeloma in patients unresponsive to prior therapies. It inhibits cancer cell growth, modulates the immune response, and reduces inflammation, often combined with dexamethasone for enhanced efficacy in relapsed or refractory cases.

Olaparib is a potent oral PARP inhibitor used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. By blocking DNA repair in cancer cells, it induces synthetic lethality, selectively targeting tumor cells and significantly improving progression-free survival in advanced malignancies.

Nintedanib is a potent, orally administered tyrosine kinase inhibitor used to treat idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and certain non-small cell lung cancers. It slows disease progression by inhibiting pathways that drive fibrosis and abnormal tissue remodeling.

Nintedanib is a potent, orally administered tyrosine kinase inhibitor used to treat idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and certain non-small cell lung cancers. It slows disease progression by inhibiting pathways that drive fibrosis and abnormal tissue remodeling.

Olaparib is a potent oral PARP inhibitor used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. By blocking DNA repair in cancer cells, it induces synthetic lethality, selectively targeting tumor cells and significantly improving progression-free survival in advanced malignancies.

Olaparib is a potent oral PARP inhibitor used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. By blocking DNA repair in cancer cells, it induces synthetic lethality, selectively targeting tumor cells and significantly improving progression-free survival in advanced malignancies.

Olaparib is a potent oral PARP inhibitor used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. By blocking DNA repair in cancer cells, it induces synthetic lethality, selectively targeting tumor cells and significantly improving progression-free survival in advanced malignancies.

Olaparib is a potent oral PARP inhibitor used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. By blocking DNA repair in cancer cells, it induces synthetic lethality, selectively targeting tumor cells and significantly improving progression-free survival in advanced malignancies.

Olaparib is a potent oral PARP inhibitor used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. By blocking DNA repair in cancer cells, it induces synthetic lethality, selectively targeting tumor cells and significantly improving progression-free survival in advanced malignancies.

Olaparib is a potent oral PARP inhibitor used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. By blocking DNA repair in cancer cells, it induces synthetic lethality, selectively targeting tumor cells and significantly improving progression-free survival in advanced malignancies.

Olaparib is a potent oral PARP inhibitor used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. By blocking DNA repair in cancer cells, it induces synthetic lethality, selectively targeting tumor cells and significantly improving progression-free survival in advanced malignancies.

Olaparib is a potent oral PARP inhibitor used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. By blocking DNA repair in cancer cells, it induces synthetic lethality, selectively targeting tumor cells and significantly improving progression-free survival in advanced malignancies.

Olaparib is a potent oral PARP inhibitor used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. By blocking DNA repair in cancer cells, it induces synthetic lethality, selectively targeting tumor cells and significantly improving progression-free survival in advanced malignancies.

Olaparib is a potent oral PARP inhibitor used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. By blocking DNA repair in cancer cells, it induces synthetic lethality, selectively targeting tumor cells and significantly improving progression-free survival in advanced malignancies.

Olaparib is a potent oral PARP inhibitor used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. By blocking DNA repair in cancer cells, it induces synthetic lethality, selectively targeting tumor cells and significantly improving progression-free survival in advanced malignancies.

Mitomycin is a potent antineoplastic agent used in the treatment of various cancers, including stomach and pancreatic cancer. It inhibits DNA synthesis, leading to cancer cell death. Also used topically in eye surgeries, it helps prevent scarring and abnormal tissue growth.

Mitomycin is a potent antineoplastic agent used in the treatment of various cancers, including stomach and pancreatic cancer. It inhibits DNA synthesis, leading to cancer cell death. Also used topically in eye surgeries, it helps prevent scarring and abnormal tissue growth.

Mitomycin is a potent antineoplastic agent used in the treatment of various cancers, including stomach and pancreatic cancer. It inhibits DNA synthesis, leading to cancer cell death. Also used topically in eye surgeries, it helps prevent scarring and abnormal tissue growth.

Pazopanib tablet is a targeted anti-cancer therapy used to treat advanced renal cell carcinoma and soft tissue sarcoma. As a tyrosine kinase inhibitor, it disrupts tumor growth and blood vessel formation, offering significant clinical benefit. It is taken orally under medical supervision.

Pazopanib tablet is a targeted anti-cancer therapy used to treat advanced renal cell carcinoma and soft tissue sarcoma. As a tyrosine kinase inhibitor, it disrupts tumor growth and blood vessel formation, offering significant clinical benefit. It is taken orally under medical supervision.

Pazopanib tablet is a targeted anti-cancer therapy used to treat advanced renal cell carcinoma and soft tissue sarcoma. As a tyrosine kinase inhibitor, it disrupts tumor growth and blood vessel formation, offering significant clinical benefit. It is taken orally under medical supervision.

Pazopanib tablet is a targeted anti-cancer therapy used to treat advanced renal cell carcinoma and soft tissue sarcoma. As a tyrosine kinase inhibitor, it disrupts tumor growth and blood vessel formation, offering significant clinical benefit. It is taken orally under medical supervision.

Pazopanib tablet is a targeted anti-cancer therapy used to treat advanced renal cell carcinoma and soft tissue sarcoma. As a tyrosine kinase inhibitor, it disrupts tumor growth and blood vessel formation, offering significant clinical benefit. It is taken orally under medical supervision.